All News ABL Bio Inc.

Equities

A298380

KR7298380007

End-of-day quote Korea S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
28,150 ^KRW	-1.05%		-2.43%	+14.43%

11/07	ABL Bio Inc. announced that it has received KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI
02/07	ABL Bio Inc. announced that it expects to receive KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	CI

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ABL Bio Inc. announced that it has received KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	11/07	CI
ABL Bio Inc. announced that it expects to receive KRW 139.999910884 billion in funding from Atinum Investment Co., Ltd, Company K Partners Limited and other investors	02/07	CI
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10/06	MT
Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates	26/03	AQ
Biocytogen and ABL Bio enter into a collaboration to jointly develop new dual-antibody ADC drugs	26/03	AQ
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates	25/03	CI
ABL Bio Taps into Synaffix ADC Technology	14/23/14	AQ
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors	22/22/22	MT
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	12/22/12	AQ
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease	12/22/12	CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting	12/21/12	CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009	08/21/08	CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting	05/21/05	CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody	04/21/04	CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody	09/21/09	CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors	06/21/06	CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors	30/21/30	CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody	14/20/14	CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific	15/20/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News ABL Bio Inc.

Equities

A298380

KR7298380007

All News

Filters